Abstract
Myeloid-derived suppressor cells (MDSC) present in the human peripheral blood, represent a heterogeneous population of cells with monocytic and granulocytic features. To provide guidelines for reliable assessments of the frequency and function of MDSC, we compared fresh vs. cryopreserved peripheral blood mononuclear cell (PBMC) samples obtained from normal controls and patients with cancer. PBMC were obtained from 4 healthy donors and 21 patients with cancer. They were stained with labeled antibodies, and the frequency of DR⁻/LIN⁻/CD11b+, DR⁻/LIN⁻/CD15+, DR⁻/LIN⁻/CD33+ and DR(-/low)/CD14+ cells was determined by flow cytometry before and after cryopreservation. CFSE-based suppressor assays were used to test inhibitory functions of MDSC. Arginase I expression and reactive oxygen species (ROS) upregulation in MDSC subsets were evaluated by flow cytometry. The DR(-/low)/CD14+ and DR⁻/LIN⁻/CD11b+ subsets of MDSC were found to be more resistant to the cryopreservation/thawing procedure compared to the DR⁻/LIN⁻/CD15+ and DR⁻/LIN⁻/CD33+ subsets. The frequency of the latter two MDSC subsets was significantly reduced after cryopreservation. All but DR⁻/LIN⁻/CD15+ cells inhibited proliferation of autologous CSFE-labeled CD4+ cells but lost suppressor activity after cryopreservation. Only DR⁻/LIN-/CD15+ cells were positive for Arginase I, but lost its expression after cryopreservation. Only fresh DR⁻/LIN⁻/CD11b+ and DR⁻/LIN⁻/CD15+ cells produced ROS after in vitro stimulation. Studies of human MDSC should be performed in fresh blood samples. If samples have to be cryopreserved, monitoring of CD11b+ and CD14+ MDSC subsets provides the most reliable results. Arginase I expression or stimulated ROS production assessed by flow cytometry are useful markers for MDSC subsets only in fresh samples.
MeSH Terms
Antigens, CD/blood
Antigens, Differentiation, Myelomonocytic/blood
Arginase/blood
Cryopreservation
Flow Cytometry/methods
Granulocytes/immunology,metabolism,pathology
HLA-DR Antigens/blood
Humans
Leukocytes, Mononuclear/immunology,metabolism,pathology
Lewis X Antigen/blood
Lipopolysaccharide Receptors/blood
Monocytes/immunology,metabolism,pathology
Myeloid Cells/immunology,metabolism,pathology
Neoplasms/blood,immunology,pathology
Reactive Oxygen Species/blood
Sialic Acid Binding Ig-like Lectin 3
Chemicals
Antigens, CD
Antigens, Differentiation, Myelomonocytic
CD33 protein, human
HLA-DR Antigens
Lewis X Antigen
Lipopolysaccharide Receptors
Reactive Oxygen Species
Sialic Acid Binding Ig-like Lectin 3
Arginase
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Kotsakis Athanasios
Departments of Pathology, Medical Oncology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Harasymczuk Malgorzata
Schilling Bastian
Georgoulias Vasilis
Argiris Athanassios
Whiteside Theresa L
References (31)
31 references, click to expand
-
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
Cancer Res. 2010 Jun 1;70(11):4335-45
PMID: 20484028
-
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.
Clin Cancer Res. 2008 Dec 15;14(24):8270-8
PMID: 19088044
-
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.
Prostate. 2010 Mar 1;70(4):443-55
PMID: 19902470
-
Myeloid derived suppressor cells in human diseases.
Int Immunopharmacol. 2011 Jul;11(7):802-7
PMID: 21237299
-
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30
PMID: 21644036
-
Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
Br J Haematol. 2011 Jun;153(5):557-67
PMID: 21477210
-
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
PMID: 18446337
-
Expression and prognostic significance of iNOS in uveal melanoma.
Int J Cancer. 2010 Jun 1;126(11):2682-9
PMID: 19847812
-
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
Cancer Res. 2005 Apr 15;65(8):3044-8
PMID: 15833831
-
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression.
J Immunol Methods. 2009 Jul 31;346(1-2):55-63
PMID: 19450601
-
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
Blood. 2000 Dec 1;96(12):3838-46
PMID: 11090068
-
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity.
Cancer Immunol Immunother. 2010 Oct;59(10):1593-600
PMID: 20414655
-
Subsets of myeloid-derived suppressor cells in tumor-bearing mice.
J Immunol. 2008 Oct 15;181(8):5791-802
PMID: 18832739
-
Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells.
Cancer Res. 2000 Jun 15;60(12):3305-12
PMID: 10866325
-
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
J Clin Oncol. 2007 Jun 20;25(18):2546-53
PMID: 17577033
-
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45
PMID: 19572148
-
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.
J Immunol. 2009 May 1;182(9):5693-701
PMID: 19380816
-
Effects of cryopreservation on lymphocyte immunophenotype and function.
J Immunol Methods. 2003 Jul;278(1-2):145-55
PMID: 12957403
-
Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity.
Cancer Res. 2001 Feb 1;61(3):1100-6
PMID: 11221839
-
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.
Cancer Res. 2006 Sep 15;66(18):9299-307
PMID: 16982775
-
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
J Immunol. 1998 Nov 15;161(10):5313-20
PMID: 9820504
-
Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation.
J Immunol Methods. 2009 Aug 15;347(1-2):87-90
PMID: 19538964
-
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
J Immunol. 2004 Jan 15;172(2):989-99
PMID: 14707072
-
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
J Immunol. 2001 Jan 1;166(1):678-89
PMID: 11123353
-
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.
J Immunol. 2004 Jan 1;172(1):464-74
PMID: 14688356
-
Arginase and ornithine, as markers in human non-small cell lung carcinoma.
Cancer Biochem Biophys. 1999 Jul;17(1-2):125-31
PMID: 10738908
-
Myeloid-derived suppressor cells in human cancer.
Cancer J. 2010 Jul-Aug;16(4):348-53
PMID: 20693846
-
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
Clin Cancer Res. 2008 Sep 15;14(18):5884-92
PMID: 18794101
-
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.
Semin Cancer Biol. 2006 Feb;16(1):53-65
PMID: 16168663
-
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Gastroenterology. 2008 Jul;135(1):234-43
PMID: 18485901
-
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
J Clin Oncol. 2008 Jul 1;26(19):3235-41
PMID: 18591558